Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,260 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium.
Chang K, Pastan I, Willingham MC. Chang K, et al. Among authors: pastan i. Int J Cancer. 1992 Feb 1;50(3):373-81. doi: 10.1002/ijc.2910500308. Int J Cancer. 1992. PMID: 1735605
Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium.
Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Chang K, et al. Among authors: pastan i. Cancer Res. 1992 Jan 1;52(1):181-6. Cancer Res. 1992. PMID: 1727378
This cytotoxicity is due to the fact that domain I of Pseudomonas exotoxin promotes internalization of antigens which are not internalized or bound to antibody alone. ...
This cytotoxicity is due to the fact that domain I of Pseudomonas exotoxin promotes internalization of antigens which are not interna …
Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and Pseudomonas exotoxin.
Prior TI, Helman LJ, FitzGerald DJ, Pastan I. Prior TI, et al. Among authors: pastan i. Cancer Res. 1991 Jan 1;51(1):174-80. Cancer Res. 1991. PMID: 1846308
The specificity of IGF-I-PE40 cytotoxicity was confirmed through competition with excess IGF-I and through blockage of toxin binding using an antibody specific to the type I IGF receptor. ...IGF-I-PE40 may be useful in the selective elimination of cell …
The specificity of IGF-I-PE40 cytotoxicity was confirmed through competition with excess IGF-I and through blockage of toxin b …
Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice.
Siegall CB, Kreitman RJ, FitzGerald DJ, Pastan I. Siegall CB, et al. Among authors: pastan i. Cancer Res. 1991 Jun 1;51(11):2831-6. Cancer Res. 1991. PMID: 1851660
IL6-PE664Glu showed improved therapeutic efficacy when released continuously for 7 days by an osmotic pump planted i.p. than when administered by multiple daily i.p. injections. ...
IL6-PE664Glu showed improved therapeutic efficacy when released continuously for 7 days by an osmotic pump planted i.p. than when adm …
Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice.
Pearson JW, FitzGerald DJ, Willingham MC, Wiltrout RH, Pastan I, Longo DL. Pearson JW, et al. Among authors: pastan i. Cancer Res. 1989 Jul 1;49(13):3562-7. Cancer Res. 1989. PMID: 2499420
The efficacy of intracavitary chemoimmunotoxin therapy for cancer treatment was evaluated using the human colon carcinoma (HT-29) which had been xenografted i.p. into nude mice. ...Mice given injections i.p. of 3 x 10(6) HT-29 ascites cells developed a localized dis …
The efficacy of intracavitary chemoimmunotoxin therapy for cancer treatment was evaluated using the human colon carcinoma (HT-29) which had …
Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines.
Pirker R, FitzGerald DJ, Hamilton TC, Ozols RF, Willingham MC, Pastan I. Pirker R, et al. Among authors: pastan i. Cancer Res. 1985 Feb;45(2):751-7. Cancer Res. 1985. PMID: 2981613
In situ hybridization analysis of acquisition and loss of the human multidrug-resistance gene.
Shen DW, Pastan I, Gottesman MM. Shen DW, et al. Among authors: pastan i. Cancer Res. 1988 Aug 1;48(15):4334-9. Cancer Res. 1988. PMID: 3390829
Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin.
Debinski W, Puri RK, Pastan I. Debinski W, et al. Among authors: pastan i. Int J Cancer. 1994 Sep 1;58(5):744-8. doi: 10.1002/ijc.2910580520. Int J Cancer. 1994. PMID: 8077061
Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
Kreitman RJ, Chang CN, Hudson DV, Queen C, Bailon P, Pastan I. Kreitman RJ, et al. Among authors: pastan i. Int J Cancer. 1994 Jun 15;57(6):856-64. doi: 10.1002/ijc.2910570615. Int J Cancer. 1994. PMID: 8206679
Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D, Kuan CT, Payne J, Kihara A, Murray A, Wang LM, Alimandi M, Pierce JH, Pastan I, Lippman ME. Yang D, et al. Among authors: pastan i. Clin Cancer Res. 1998 Apr;4(4):993-1004. Clin Cancer Res. 1998. PMID: 9563895
Members of the type I receptor tyrosine kinase family, including epidermal growth factor (EGF) receptor (EGFR) and ErbB-2/neu, are often overexpressed in various human cancer cells, including breast. ...Continuous i.p. administration of EGF-like domain of HRGbeta1-P …
Members of the type I receptor tyrosine kinase family, including epidermal growth factor (EGF) receptor (EGFR) and ErbB-2/neu, are of …
1,260 results
Jump to page
Feedback